Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $11.30, but opened at $11.93. Sionna Therapeutics shares last traded at $11.78, with a volume of 6,354 shares.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price target on the stock. TD Cowen began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating for the company. Finally, Stifel Nicolaus started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price target on the stock.
Get Our Latest Research Report on SION
Sionna Therapeutics Trading Down 2.9 %
The company has a fifty day simple moving average of $13.01.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.68) by ($0.70).
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
